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Conclusions. Although it is not statistically signiﬁcant, this result conﬁrms that there is not concordance between two tests,
therefore we could not use the MRI to predict the surgical ﬁndings.
http://dx.doi.org/10.1016/j.rpor.2013.03.747
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Introduction. Preoperative chemoradiation in advanced rectal cancer increases locoregional control rates and sphincter preserva-
tion. Different schedules are used, mainly the short course (25Gy, 5Gy/fraction) and standard fractionation (50Gy, 2Gy/fraction).
We do not know the value of other schemes such as the hyperfractionation. No studies comparing standard and hyperfraction-
ated fractionation have been published at present time. The percentage of pathological complete remission after preoperative
chemoradiation is considered to have predictive value in terms of local control and survival in a recently publishedmeta-analysis.
Objectives. To compare pathologic complete remission rates of patients treated with capecitabine and hyperfractionation vs.
capecitabine and standard fractionation in our center.
Material and methods. Until 2008 were treated in our department 50 patients diagnosed with rectal carcinoma T3 or N + with
preoperative hyperfractionated irradiation (50.60Gy, 1.15Gy per fraction, two fraction a day) and capecitabine and between
November 2010 and January 2012, 21 patients treated with standard fractionation (50.4Gy, 1.8Gy per fraction) and capecitabine.
Results. The mean age was 62.5 years in the hyperfractionation arm, mean distance from anal verge was 7.7 cm; type of surgery:
anterior resection (78%), abdominoperineal resection (30%), other (2%). The median age was 61 years in standard fractionation.
Median distance 7.8 cm from the anal verge; type of surgery: anterior resection (80.95%), abdominoperineal resection (19.05%).
The pathologic complete remission rates with hyperfractionated schedules was 20% vs 14% for standard arm, p=0.09. Given the
short follow up of patients treated with standard fractionation no local recurrences were evaluated.
Conclusions. Hyperfractionated radiotherapy aimed a higher percentage of complete pathologic response probably the loss of
signiﬁcant statistical differences is due to the small numbers of patients. More comparative studies are needed.
http://dx.doi.org/10.1016/j.rpor.2013.03.748
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Introduction. Recent trials suggest that short-term and classical preoperative radiotherapy (PR) term plus chemotherapy (QT) are
similar looking at local control, toxicity, overall survival and quality of life.
Objective. To present the long-results and early toxicity of a short-term (ST) regimen of high-dose PR (5×5Gy) followed by surgery
within 1–2 weeks.
Methods. Between April 1999 and July 2007, 139 pts with RRC were prospectively treated with ST PR plus total mesorectal excision
(TME). Median follow up was 78 months. Statistical analysis was performed using SPSS-20.
Results. 97 males and 42 females. Median age was 67.5 (41–86). Clinical stage in transanal ultrasound (TU) was: 16 TX, 4 T1, 25 T2,
72 T3, 2 T4, 57 N0, and 48 N1. 20 pts could not be staged by TU. Free circumferential mesorectal margin (CMM) was identiﬁed in
72 pts by MRI. Median distance between anal margin and tumour was 8.6 cm (1–20). Median CEA levels were 5.7ng/ml (0.3–57.9).
Median time between PR and surgery (S) was 11.1 days, surgical procedure was anterior resection, 106 pts, abdominoperineal
resection, 27 pts and pelvic anterior exenteration 2 pts, all of them with TME, Hartman 4 pts. Pathologic stage was 1 pT0, 4
pT1, 37 pT2, 93 pT3, 4 pT4, 83 pN0, 28 pN1 and 28 pN2. Stage I 34 pts (24.5%), II 49 pts (35.3%), and III 56 pts (40.3%). Adjuvant
chemotherapy was administered in 73 pts, (Mayo Clinic regimen) in 57 pts. Interval between QT and surgery was 50.6 days. The
overall survival was 46.8% at 10 years, disease free survival was 79.1% at 10 years, by stages: Stage I 94.1%, II 81.6%, and III 67.9%,
at 10 years. Local recurrence 6 pts (4.31%).
Conclusions. Our results conﬁrm the equivalence of the short-term regimen with other classical regimens.
http://dx.doi.org/10.1016/j.rpor.2013.03.749
